Literature DB >> 26062687

[Hyperkalemia : what can we expect from new potassium-lowering drugs?].

R Schmitt1.   

Abstract

Hyperkalemia is a common clinical problem. While several options are available to treat acute hyperkalemia, there are few options for long-term treatment. The use of oral potassium binders might be such an option. Sodium zirconium cyclosilicate and patiromer are two new oral potassium binders awaiting approval. The efficacy of these novel potassium-lowering agents were tested in several phase 3 short-term studies published in late 2014.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26062687     DOI: 10.1007/s00108-015-3677-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  19 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

Review 2.  Asking the question again: are cation exchange resins effective for the treatment of hyperkalemia?

Authors:  Kamel S Kamel; Martin Schreiber
Journal:  Nephrol Dial Transplant       Date:  2012-09-17       Impact factor: 5.992

Review 3.  Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status.

Authors:  Terry K W Ma; Kevin K H Kam; Bryan P Yan; Yat-Yin Lam
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

4.  Sodium zirconium cyclosilicate in hyperkalemia.

Authors:  David K Packham; Henrik S Rasmussen; Philip T Lavin; Mohamed A El-Shahawy; Simon D Roger; Geoffrey Block; Wajeh Qunibi; Pablo Pergola; Bhupinder Singh
Journal:  N Engl J Med       Date:  2014-11-21       Impact factor: 91.245

5.  Damned if you do, damned if you don't: potassium binding resins in hyperkalemia.

Authors:  Maura Watson; Kevin C Abbott; Christina M Yuan
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-26       Impact factor: 8.237

6.  Management of hyperkalemia in hospitalized patients.

Authors:  Kristy N Fordjour; Ted Walton; John J Doran
Journal:  Am J Med Sci       Date:  2014-02       Impact factor: 2.378

Review 7.  The effect of RAAS blockade on the progression of diabetic nephropathy.

Authors:  Sara S Roscioni; Hiddo J Lambers Heerspink; Dick de Zeeuw
Journal:  Nat Rev Nephrol       Date:  2013-12-03       Impact factor: 28.314

8.  2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension.

Authors: 
Journal:  J Hypertens       Date:  2013-10       Impact factor: 4.844

Review 9.  The past, present and future of renin-angiotensin aldosterone system inhibition.

Authors:  Robert J Mentz; George L Bakris; Bernard Waeber; John J V McMurray; Mihai Gheorghiade; Luis M Ruilope; Aldo P Maggioni; Karl Swedberg; Ileana L Piña; Mona Fiuzat; Christopher M O'Connor; Faiez Zannad; Bertram Pitt
Journal:  Int J Cardiol       Date:  2012-10-31       Impact factor: 4.164

10.  To bind or to let loose: effectiveness of sodium polystyrene sulfonate in decreasing serum potassium.

Authors:  Shaifali Sandal; Hatim Karachiwala; John Noviasky; Dongliang Wang; William C Elliott; David F Lehmann
Journal:  Int J Nephrol       Date:  2012-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.